Asia Pacific Oligonucleotide Synthesis Market

The Asia Pacific oligonucleotide synthesis market is expected to reach USD 4.88 billion by 2030, from USD 2.08 billion in 2025, with a CAGR of 18.5%.

Asia Pacific is experiencing an increase in genomics spending, mainly driven by China, Japan, South Korea, India, and Singapore, among others. National sequencing programs and hospital-led precision medicine initiatives are expanding each year. This is leading to more labs performing routine PCR and NGS workflows. Moreover, as lab throughput increases, purchasing shifts from occasional orders to repeated, high-volume procurement. There is strong demand for primers and probes for qPCR, as well as adapters and index oligos for NGS library preparation. Research groups and test developers are also ordering more custom DNA/RNA oligos for assay development and validation.

The Asia Pacific oligonucleotide synthesis market is competitive. Key market players are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Agilent Technologies, Inc. (US), among others.

To know about the assumptions considered for the study download the pdf brochure

In April 2024, Nippon Shinyaku, Co., Ltd. entered into a joint research agreement with MINA Therapeutics to potentially develop nucleic acid drugs to treat rare diseases of the central nervous system. Through this agreement, MINA Therapeutics will provide Nippon Shinyaku RNAa therapeutics, which are oligonucleotides that can increase the transcription of a target gene. In July 2023, Astellas Pharma Inc. acquired IVERIC Bio, Inc. for ~USD 10 million, to expand its capabilities in the ophthalmology disease area.

Danaher Corporation plays a significant role in the Asia Pacific oligonucleotide synthesis market. The company primarily provides relevant products through Integrated DNA Technologies (IDT). IDT is well known among universities, clinical laboratories, and test developers across Asia Pacific for its custom DNA/RNA oligos and high-volume qPCR primers and probes. It is also a common supplier for NGS adapters and index oligos, which are frequently ordered as sequencing becomes more routine. Danaher benefits from a large and diverse regional customer base.

Thermo Fisher Scientific, Inc. is a key company in the Asia Pacific oligonucleotide synthesis market, serving both research and diagnostic end users. It provides a comprehensive molecular workflow portfolio across the region, including custom DNA/RNA oligos, PCR, and qPCR reagents. This facilitates assay components that laboratories can purchase as a combined solution. Thermo Fisher is widely trusted for primer- and probe-based testing in routine clinical and research workflows, including assay development and high-throughput testing setups.

Biogen Inc. is a key player in the Asia Pacific oligonucleotide synthesis market. Its portfolio includes SPINRAZA (Nusinersen), used to treat spinal muscular atrophy, and QALSODY (Tofersen), used for Amyotrophic Lateral Sclerosis (ALS). These treatments are steadily driving demand for oligonucleotide therapeutics. Additionally, their availability to a large population across various regions, such as the Asia Pacific, is increasing, thereby supporting market growth.

Market Ranking

The Asia Pacific oligonucleotide synthesis market is becoming more organized and increasingly quality-focused. For research and diagnostic oligos, Danaher is a leading supplier through IDT, with extensive presence across Asia Pacific academic labs, clinical labs, and test developers. It supports high-volume custom DNA/RNA oligos, routine qPCR primers/probes, and NGS adapters and indexes, where consistent lots and reliable turnaround times are essential. Thermo Fisher is a major player due to its broad workflow integration. It benefits from bundling PCR and NGS consumables and its wide distribution network, which drives repeat demand for routine testing and lab workflows. For oligo-based drugs, Alnylam is a strong global demand driver through its siRNA medicine portfolio, which promotes repeated manufacturing cycles and commercial-grade requirements that impact supply chains. Biogen also supports therapeutic demand through its ASO medicines (examples include SPINRAZA and QALSODY), highlighting the need for high-purity, tightly controlled oligo drug substances.

Related Reports:

Asia Pacific Oligonucleotide Synthesis Market by Product {Drugs [ASO, siRNA], Synthesized Oligos [Product (Primers, Probes), Type (Custom, Predesigned)], Reagents, Equipment}, Application (Therapeutic, Research, Diagnostics) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com